TRANS GENIC GROUP INC. Logo

TRANS GENIC GROUP INC.

Biotech firm offering drug discovery support and investment/consulting services.

2342 | T

Overview

Corporate Details

ISIN(s):
JP3635720000
LEI:
Country:
Japan
Address:
福岡市中央区天神二丁目3番36号

Description

TRANS GENIC GROUP INC. is a biotechnology company that operates through two main business segments: Drug Discovery Support and Investment & Consulting. The Drug Discovery Support division provides comprehensive services across the entire drug development pipeline, from basic research to non-clinical and clinical trials. Core services include the contract production of genetically modified animals, particularly mice, using genome editing technologies like CRISPR/Cas9. The company also specializes in contract antibody production, glycosylation analysis, and the supply of model mice. The Investment & Consulting segment focuses on M&A, business succession, and providing advisory and support services for business revitalization.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 02:36
確認書
Japanese 8.2 KB
2025-11-13 02:33
半期報告書-第28期(2025/04/01-2026/03/31)
Japanese 189.2 KB
2025-08-01 09:45
訂正確認書
Japanese 8.2 KB
2025-08-01 09:44
訂正有価証券報告書-第27期(2024/04/01-2025/03/31)
Japanese 667.3 KB
2025-07-02 05:53
訂正臨時報告書
Japanese 24.4 KB
2025-07-01 10:02
臨時報告書
Japanese 24.4 KB
2025-06-30 09:38
確認書
Japanese 8.6 KB
2025-06-30 09:37
内部統制報告書-第27期(2024/04/01-2025/03/31)
Japanese 23.7 KB
2025-06-30 09:34
有価証券報告書-第27期(2024/04/01-2025/03/31)
Japanese 1.1 MB
2025-06-13 10:13
臨時報告書
Japanese 21.2 KB
2025-04-23 09:55
臨時報告書
Japanese 20.1 KB
2024-11-13 02:42
確認書
Japanese 8.5 KB
2024-11-13 02:41
半期報告書-第27期(2024/04/01-2025/03/31)
Japanese 191.9 KB
2024-06-24 08:30
臨時報告書
Japanese 19.8 KB
2024-06-21 07:03
有価証券報告書-第26期(2023/04/01-2024/03/31)
Japanese 1.0 MB

Automate Your Workflow. Get a real-time feed of all TRANS GENIC GROUP INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TRANS GENIC GROUP INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TRANS GENIC GROUP INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

BioSenic SA Logo
Develops therapies for autoimmune diseases, inflammation, and bone disorders.
Belgium
BIOS
BIOTECH Logo
A biotechnology group offering preclinical services, intein development, and licensing.
Spain
BST
Biovica International B Logo
Develops blood-based biomarker assays for cancer therapy monitoring.
Sweden
BIOVIC
Bonus BioGroup Ltd. Logo
A clinical-stage biotech firm developing cell therapy and tissue engineering products.
Israel
BONS
BRAIN Biotech AG Logo
Develops enzymes and microorganisms for the food, chemical, and life sciences sectors.
Germany
BNN
BriaCell Therapeutics Corp. Logo
Clinical-stage immuno-oncology company developing cellular immunotherapies for cancer.
United States of America
BCTX
BSF ENTERPRISE PLC Logo
Develops cell-based solutions for cultivated meat, leather, and corneal repair.
United Kingdom
BSFA
BullFrog AI Holdings, Inc. Logo
A technology company applying AI and machine learning to drug development.
United States of America
BFRG
Burning Rock Biotech Ltd Logo
A global diagnostics company specializing in precision oncology using NGS technology.
United States of America
BNR
Cabaletta Bio, Inc. Logo
Develops engineered T cell therapies for B cell-mediated autoimmune diseases.
United States of America
CABA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.